{
    "clinical_study": {
        "@rank": "97273", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D2", 
                "arm_group_type": "Active Comparator", 
                "description": "a single oral dose of vitamin D2"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "a single oral dose of a placebo"
            }, 
            {
                "arm_group_label": "Vitamin D3", 
                "arm_group_type": "Experimental", 
                "description": "A single oral dose of vitamin D3"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacokinetic 25(OH)D and 1,25(OH)2D responses\n      to a single oral dose of vitamin D2 or vitamin D3 in a group of Stage 5-Chronic Kidney\n      Disease subjects requiring chronic hemodialysis."
        }, 
        "brief_title": "Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney Disease Patients on Chronic Hemodialysis", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, single blind, controlled study. Subjects will be randomly assigned to\n      receive 1) placebo capsules (control group); 2) capsules with ergocalciferol (the vitamin D2\n      group); or 3) capsules with cholecalciferol (the vitamin D3 group)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  30 men and women, ages 20-65, BMI 18-30, requiring chronic hemodialysis\n\n        Exclusion Criteria:\n\n          -  They will habitually consume less than 16 oz of milk per day and get less than 10\n             hours of sun exposure per week. We will exclude those with granulomatous conditions,\n             cirrhotic liver disease, and those taking anticonvulsants, barbiturates, or steroids\n             in any form or any investigational drugs within 4 weeks. We will exclude those with\n             pregnancy or planned pregnancy, hypercalcemia (>10.4 mg/dl) previously recorded,\n             chronic GI disease which would interfere with absorption, any allergy to vitamin D3,\n             or chronic vitamin D intake >1,000 IU daily. Subjects will continue to take a\n             calcitriol analogue and phosphorus binder as prescribed by their nephrologist.\n             Calcitriol analogues are to be documented and remain constant throughout study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675557", 
            "org_study_id": "Creighton15"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D3", 
                "description": "a single oral dose of vitamin D3", 
                "intervention_name": "Vitamin D3", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Cholecalciferol"
            }, 
            {
                "arm_group_label": "Vitamin D2", 
                "description": "a single oral dose of vitamin D2", 
                "intervention_name": "Vitamin D2", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "ergocalciferol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "a single oral dose of placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Ergocalciferols", 
                "Vitamin D", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "chronic kidney disease", 
        "lastchanged_date": "May 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Omaha", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68131"
                }, 
                "name": "Creighton University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney", 
        "overall_official": {
            "affiliation": "Creighton University", 
            "last_name": "Laura AG Armas, MD,MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "25(OH)D levels will be drawn at intervals over 16 weeks.", 
            "measure": "25(OH)D", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675557"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Creighton University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Creighton University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}